Abstract
Hepatitis C virus (HCV) infection is a major health problem worldwide. Approximately, 170-200 million individuals are chronically infected worldwide and a quarter of these patients are at increased risk of developing liver cirrhosis, hepatocellular carcinoma and even liver failure.
A complete eradication of the virus is one of the most important treatment goals for antiviral research. In 2011, the first-generation protease inhibitors boceprevir (BOC) telaprevir (TVR) were approved by FDA as the direct-acting antiviral agents. A number of promising new direct-acting antiviral agents (DAAs) have been developed in the past few years. Due to their increased efficacy, safety, and tolerability, interferon-free oral therapies with DAAs are in use for patients with chronic HCV and cirrhosis patients. In this review, we will discuss the results of clinical trials of several DAAs and the approved combinations, including NS3/4A protease inhibitors, NS5A inhibitors, and NS5B inhibitors. A number of drugs, including Sovaldi®, Harvoni® Viekira Pak®, Epclusa®, Zepatier® have been approved by FDA in the past two-three years. The latest advancement of DAA therapy and related side effects due to the therapy are also discussed.
Keywords: DAA, Drug, HCV, hepatitis C virus, inhibitor, NS3, NS3/4A, NS4A, NS5A, NS5B.
Mini-Reviews in Medicinal Chemistry
Title:Recent Advancement of Direct-acting Antiviral Agents (DAAs) in Hepatitis C Therapy
Volume: 18 Issue: 7
Author(s): Debasis Das*Mayank Pandya
Affiliation:
- Department of Chemistry, School of Science, RK University, Rajkot-360020, Gujarat,India
Keywords: DAA, Drug, HCV, hepatitis C virus, inhibitor, NS3, NS3/4A, NS4A, NS5A, NS5B.
Abstract: Hepatitis C virus (HCV) infection is a major health problem worldwide. Approximately, 170-200 million individuals are chronically infected worldwide and a quarter of these patients are at increased risk of developing liver cirrhosis, hepatocellular carcinoma and even liver failure.
A complete eradication of the virus is one of the most important treatment goals for antiviral research. In 2011, the first-generation protease inhibitors boceprevir (BOC) telaprevir (TVR) were approved by FDA as the direct-acting antiviral agents. A number of promising new direct-acting antiviral agents (DAAs) have been developed in the past few years. Due to their increased efficacy, safety, and tolerability, interferon-free oral therapies with DAAs are in use for patients with chronic HCV and cirrhosis patients. In this review, we will discuss the results of clinical trials of several DAAs and the approved combinations, including NS3/4A protease inhibitors, NS5A inhibitors, and NS5B inhibitors. A number of drugs, including Sovaldi®, Harvoni® Viekira Pak®, Epclusa®, Zepatier® have been approved by FDA in the past two-three years. The latest advancement of DAA therapy and related side effects due to the therapy are also discussed.
Export Options
About this article
Cite this article as:
Das Debasis*, Pandya Mayank, Recent Advancement of Direct-acting Antiviral Agents (DAAs) in Hepatitis C Therapy, Mini-Reviews in Medicinal Chemistry 2018; 18 (7) . https://dx.doi.org/10.2174/1389557517666170913111930
DOI https://dx.doi.org/10.2174/1389557517666170913111930 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
Natural Products in Drug Discovery
Natural products have always been one of the important ways of drug discovery due to their novel skeleton and diverse functional group characteristics. According to statistics, between 1981 and 2019, the FDA approved a total of 1,394 small molecule drugs for marketing, of which 930 marketed drugs originated from the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nanoparticles in the Development of Therapeutic Cancer Vaccines
Pharmaceutical Nanotechnology Therapeutic Blockade of TCR Signal Transduction and Co-Stimulation in Autoimmune Disease
Current Drug Targets - Inflammation & Allergy Applications of Barton-McCombie Reaction in Total Syntheses
Current Organic Synthesis Flavonoids as Anticancer Agents: Structure-Activity Relationship Study
Current Medicinal Chemistry - Anti-Cancer Agents Target Sites for the Design of Anti-trypanosomatid Drugs Based on the Structure of Dihydroorotate Dehydrogenase
Current Pharmaceutical Design Functional Genomic Approaches Targeting the Wnt Signaling Network
Current Drug Targets Macrocyclic Hepatitis C Virus NS3/4A Protease Inhibitors: An Overview of Medicinal Chemistry
Current Medicinal Chemistry 5-Benzylidene-3,4-dihalo-furan-2-one derivatives inhibit human leukemia cancer cells through suppression of NF-κB and GSK-3β
Anti-Cancer Agents in Medicinal Chemistry Novel Approach to the Role of NMDA Receptors in Traumatic Brain Injury
CNS & Neurological Disorders - Drug Targets Nucleic Acid-based Molecular Treatment of Allergy
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Pulmonary Surfactant Proteins A and D: Innate Immune Functions and Biomarkers for Lung Diseases
Current Pharmaceutical Design Silibinin – A Promising New Treatment for Cancer
Anti-Cancer Agents in Medicinal Chemistry Relation Between Obstructive Sleep Apnea Syndrome and Resistant Hypertension - The Tip of the Iceberg
Current Respiratory Medicine Reviews Synthetic Glucocorticoids: Antenatal Administration and Long-term Implications
Current Pharmaceutical Design Unsafe Abortion: The Silent Endemic; An Avoidable Cause of Maternal Mortality. A Review
Current Women`s Health Reviews Chagas Disease: Progress and New Perspectives
Current Medicinal Chemistry Haptoglobin Genotype Affects Inflammation after Aneurysmal Subarachnoid Hemorrhage
Current Neurovascular Research SHP-2 Regulates Growth Factor Dependent Vascular Signalling and Function
Mini-Reviews in Medicinal Chemistry Mesenchymal Stem Cells: A Potent Cell Source for COVID-19
Coronaviruses Selective Sigma-1 (σ1) Receptor Antagonists: Emerging Target for the Treatment of Neuropathic Pain
Central Nervous System Agents in Medicinal Chemistry